Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.115 USD | -1.33% | -1.35% | +0.46% |
Evolution of the average Target Price on Lineage Cell Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Lineage Cell Therapeutics, Inc.
Baird | |
B. Riley | |
Noble Capital | |
Chardan | |
Cantor Fitzgerald |
EPS Revisions
- Stock Market
- Equities
- LCTX Stock
- Consensus Lineage Cell Therapeutics, Inc.